Tyrosine administration does not affect desipramine-induced dopamine levels as measured in vivo in prefrontal cortex.
Using in vivo microdialysis, we examined whether tyrosine administration would potentiate the desipramine (DMI)-induced elevation of medial prefrontal cortex (MPFC) dopamine (DA) levels. DMI (10 or 20 mg/kg IP) increased MPFC DA levels but not DOPA accumulation. Tyrosine (12.5-100 mug/ml) administered by reverse microdialysis did not affect DMI-induced MPFC DA levels. The data support our hypothesis that DA synthesis must be significantly increased in order for administered tyrosine to increase extracellular DA levels.
Bongiovanni
Rodolfo
R
Louis Stokes Department of Veterans Affairs Medical Center, Case Western Reserve University, 10000 Brecksville Road, Brecksville, OH 44141, USA.
Kirkbride
Bobbi
B
Walmire
Peter
P
Jaskiw
George E
GE
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000704:Analysis of Variance; D000818:Animals; D003891:Desipramine / Q000494:pharmacology*; D004298:Dopamine / Q000378:metabolism*; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006834:Hydrazines / Q000494:pharmacology; D008297:Male; D017551:Microdialysis / Q000379:methods; D017397:Prefrontal Cortex / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors; D014443:Tyrosine / Q000008:administration & dosage*
D004791:Enzyme Inhibitors; D006834:Hydrazines; D015102:3,4-Dihydroxyphenylacetic Acid; D014443:Tyrosine; C004297:3-hydroxybenzylhydrazine; D003891:Desipramine; D004298:Dopamine